Core Viewpoint - The company has obtained a drug production license for lactulose active pharmaceutical ingredient, marking a significant milestone in its strategic expansion into the raw material and health sectors [1][2]. Group 1: License Details - The drug production license was issued by the Shandong Provincial Drug Administration, with the license number Lu20250024, valid until October 28, 2030 [1]. - The production facility is located in the Yucheng High-tech Industrial Development Zone, Shandong Province, and is authorized to produce lactulose solution for registered use only [1]. Group 2: Impact on the Company - The acquisition of the drug production license accelerates the application, registration, and market launch processes for lactulose, initiating the company's diversification into raw materials [2]. - This milestone is seen as a key leverage point for enhancing industry value and strengthening market competitiveness, aligning with the company's goal to establish itself as a world-class provider of functional and health solutions [2]. - Currently, lactulose is only exported to select overseas markets, but future approvals in domestic and major global markets are expected to boost sales revenue and operational performance, although the immediate impact on current performance is anticipated to be minimal [2].

Core Viewpoint - The company, Baolingbao (002286.SZ), has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the application, registration, and market launch process for its first active pharmaceutical ingredient, lactulose, marking the beginning of the company's diversification in raw materials [1] Group 1 - The acquisition of the Drug Manufacturing License is a significant regulatory milestone for the company [1] - The approval facilitates the subsequent steps for the company's first raw material drug, lactulose [1] - This development represents the start of the company's strategy to diversify its raw material offerings [1]

Core Viewpoint - The company, Baolingbao (002286), has recently obtained a "Drug Production License" from the Shandong Provincial Drug Administration, which allows it to produce the raw material drug lactulose solution, marking the beginning of its diversification into raw material drugs [1] Group 1 - The acquisition of the "Drug Production License" accelerates the subsequent application, registration, and market launch processes for the company's first raw material drug, lactulose [1] - This license represents a significant step in the company's strategy to diversify its raw material drug offerings [1]

Core Viewpoint - The company Baolingbao (002286.SZ) has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the registration and market launch process for its first active pharmaceutical ingredient, lactulose solution [1] Group 1 - The Drug Manufacturing License was issued for the production site located at No. 1, East Outer Ring Road, Yucheng, High-tech Industrial Development Zone, Dezhou, Shandong [1] - The license specifically allows for the production of lactulose solution for registered declaration use only, marking a significant step in the company's diversification into active pharmaceutical ingredients [1] - This achievement is seen as the beginning of the company's strategy to expand its portfolio in the pharmaceutical sector [1]

Core Viewpoint - The company has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the registration and market launch process for its first active pharmaceutical ingredient, lactulose solution, marking the beginning of its diversification in the active pharmaceutical ingredient sector [1] Group 1 - The Drug Manufacturing License was issued for the production site located at No. 1, East Outer Ring Road, Yucheng, High-tech Industrial Development Zone, Dezhou, Shandong [1] - The license specifically pertains to the active pharmaceutical ingredient lactulose solution, which is limited to registered declaration use [1] - The acquisition of this license is a significant step for the company in expanding its portfolio of active pharmaceutical ingredients [1]